Targeted therapies in non-small cell lung cancer—Beyond EGFR and ALK

Cancers

Volumn 7, Issue 2, 2015, Pages 930-949

  Rothschild, Sacha I ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

BRAF; C MET; DDR2; FGFR1; HER2; Lung cancer; Oncogene; RET; ROS1; Targeted cancer therapy

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AFATINIB; B RAF KINASE INHIBITOR; CABOZANTINIB; CERITINIB; CRIZOTINIB; DABRAFENIB; DACOMITINIB; DOCETAXEL; ERLOTINIB; FICLATUZUMAB; FORETINIB; HEAT SHOCK PROTEIN 90 INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NERATINIB; ONARTUZUMAB; PEMETREXED; PERTUZUMAB; PF 06463922; PLACEBO; PROTEIN KINASE B INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RILOTUMUMAB; SELUMETINIB; TEMSIROLIMUS; TRAMETINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEMURAFENIB; [2 [[5 CHLORO 2 [[4 [4 (DIMETHYLAMINO) 1 PIPERIDINYL] 2 METHOXYPHENYL]AMINO] 4 PYRIMIDINYL]AMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE;

ALK GENE; ANTINEOPLASTIC ACTIVITY; DRUG EFFICACY; DRUG RESISTANCE; DRUG RESPONSE; DRUG TARGETING; EGFR GENE; FEBRILE NEUTROPENIA; GENE; GENE MUTATION; GENE REARRANGEMENT; GENE TRANSLOCATION; HUMAN; LUNG ADENOCARCINOMA; MOLECULARLY TARGETED THERAPY; NEUTROPENIA; NON SMALL CELL LUNG CANCER; NONHUMAN; ONCOGENE; PERSONALIZED MEDICINE; PNEUMONIA; REVIEW; ROS1 GENE; SYSTEMIC THERAPY; UNSPECIFIED SIDE EFFECT;

EID: 84930939429     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers7020816     Document Type: Review

References (132)

1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2015. CA Cancer J. Clin. 2015, 65, 5-29. [CrossRef] [PubMed]
2. Travis, W., Brambilla, E., Mueller-Hermelink, H., Harris, C., Harris, C., Eds. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart, 3rd ed.; World Health Organization Classification of Tumours, WHO: Geneva, Switzerland, 2004; Volume 10.
3. Paez, J.G.; Janne, P.A.; Lee, J.C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F.J.; Lindeman, N.; Boggon, T.J. et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004, 304, 1497-1500. [CrossRef] [PubMed]
4. Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.; Haserlat, S.M.; Supko, J.G.; Haluska, F.G. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350, 2129-2139. [CrossRef] [PubMed]
5. Kwak, E.L.; Bang, Y.J.; Camidge, D.R.; Shaw, A.T.; Solomon, B.; Maki, R.G.; Ou, S.H.; Dezube, B.J.; Janne, P.A.; Costa, D.B. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 2010, 363, 1693-1703. [CrossRef] [PubMed]
6. Shaw, A.T.; Kim, D.W.; Nakagawa, K.; Seto, T.; Crino, L.; Ahn, M.J.; de Pas, T.; Besse, B.; Solomon, B.J.; Blackhall, F. et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 2013, 368, 2385-2394. [CrossRef] [PubMed]
7. Kris, M.G.; Johnson, B.E.; Berry, L.D.; Kwiatkowski, D.J.; Iafrate, A.J.; Wistuba, I.I.; Varella-Garcia, M.; Franklin, W.A.; Aronson, S.L.; Su, P.-F. et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014, 311, 1998-2006. [CrossRef] [PubMed]
8. Oxnard, G.R.; Binder, A.; Jänne, P.A. New targetable oncogenes in non-small-cell lung cancer. J. Clin. Oncol. 2013, 31, 1097-1104. [CrossRef] [PubMed]
9. Birchmeier, C.; O’Neill, K.; Riggs, M.; Wigler, M. Characterization of ROS1 cDNA from a human glioblastoma cell line. Proc. Natl. Acad. Sci. USA 1990, 87, 4799-4803. [CrossRef] [PubMed]
10. Birchmeier, C.; Sharma, S.; Wigler, M. Expression and rearrangement of the ROS1 gene in human glioblastoma cells. Proc. Natl. Acad. Sci. USA 1987, 84, 9270-9274. [CrossRef] [PubMed]
11. Charest, A.; Wilker, E.W.; McLaughlin, M.E.; Lane, K.; Gowda, R.; Coven, S.; McMahon, K.; Kovach, S.; Feng, Y.; Yaffe, M.B. et al. ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. Cancer Res. 2006, 66, 7473-7481. [CrossRef] [PubMed]
12. Charest, A.; Lane, K.; McMahon, K.; Park, J.; Preisinger, E.; Conroy, H.; Housman, D. Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21). Genes Chromosomes Cancer 2003, 37, 58-71. [CrossRef] [PubMed]
13. Rikova, K.; Guo, A.; Zeng, Q.; Possemato, A.; Yu, J.; Haack, H.; Nardone, J.; Lee, K.; Reeves, C.; Li, Y. et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007, 131, 1190-1203. [CrossRef] [PubMed]
14. Takeuchi, K.; Soda, M.; Togashi, Y.; Suzuki, R.; Sakata, S.; Hatano, S.; Asaka, R.; Hamanaka, W.; Ninomiya, H.; Uehara, H. et al. RET, ROS1 and ALK fusions in lung cancer. Nat. Med. 2012, 18, 378-381. [CrossRef] [PubMed]
15. Bergethon, K.; Shaw, A.T.; Ou, S.H.; Katayama, R.; Lovly, C.M.; McDonald, N.T.; Massion, P.P.; Siwak-Tapp, C.; Gonzalez, A.; Fang, R. et al. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol. 2012, 30, 863-870. [CrossRef] [PubMed]
16. Davies, K.D.; Le, A.T.; Theodoro, M.F.; Skokan, M.C.; Aisner, D.L.; Berge, E.M.; Terracciano, L.M.; Cappuzzo, F.; Incarbone, M.; Roncalli, M. et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin. Cancer Res. 2012, 18, 4570-4579. [CrossRef] [PubMed]
17. Shaw, A.T.; Ou, S.-H.I.; Bang, Y.-J.; Camidge, D.R.; Solomon, B.J.; Salgia, R.; Riely, G.J.; Varella-Garcia, M.; Shapiro, G.I.; Costa, D.B. et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N. Engl. J. Med. 2014. [CrossRef]
18. Mazieres, J.; Zalcman, G.; Crino, L.; Biondani, P.; Barlesi, F.; Filleron, T.; Dingemans, A.M.; Léna, H.; Monnet, I.; Rothschild, S.I. et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: Results from the EUROS1 cohort. J. Clin. Oncol. 2015, 33, 992-999. [CrossRef] [PubMed]
19. Awad, M.M.; Katayama, R.; McTigue, M.; Liu, W.; Deng, Y.-L.; Brooun, A.; Friboulet, L.; Huang, D.; Falk, M.D.; Timofeevski, S. et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N. Engl. J. Med. 2013, 368, 2395-2401. [CrossRef] [PubMed]
20. Davies, K.D.; Mahale, S.; Astling, D.P.; Aisner, D.L.; Le, A.T.; Hinz, T.K.; Vaishnavi, A.; Bunn, P.A.; Heasley, L.E.; Tan, A.-C. et al. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. PLoS ONE 2013, 8, e82236. [CrossRef] [PubMed]
21. Song, A.; Kim, T.M.; Kim, D.-W.; Kim, S.; Keam, B.; Lee, S.-H.; Heo, D.S. Molecular changes associated with acquired resistance to crizotinib in ROS1-rearranged non-small cell lung cancer (NSCLC). Clin. Cancer Res. 2015. [CrossRef]
22. Katayama, R.; Kobayashi, Y.; Friboulet, L.; Lockerman, E.L.; Koike, S.; Shaw, A.T.; Engelman, J.A.; Fujita, N. Cabozantinib overcomes crizotinib resistance in ROS1 fusion positive cancer. Clin. Cancer Res. 2014, 21, 166-174. [CrossRef] [PubMed]
23. Katayama, R.; Khan, T.M.; Benes, C.; Lifshits, E.; Ebi, H.; Rivera, V.M.; Shakespeare, W.C.; Iafrate, A.J.; Engelman, J.A.; Shaw, A.T. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc. Natl. Acad. Sci. USA 2011, 108, 7535-7540. [CrossRef] [PubMed]
24. Davare, M.A.; Saborowski, A.; Eide, C.A.; Tognon, C.; Smith, R.L.; Elferich, J.; Agarwal, A.; Tyner, J.W.; Shinde, U.P.; Lowe, S.W. et al. Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins. Proc. Natl. Acad. Sci. USA 2013, 110, 19519-19524. [CrossRef] [PubMed]
25. Zou, H.Y.; Li, Q.; Engstrom, L.D.; West, M.; Appleman, V.; Wong, K.A.; McTigue, M.; Deng, Y.-L.; Liu, W.; Brooun, A. et al. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. Proc. Natl. Acad. Sci. USA 2015, 112, 3493-3498. [CrossRef] [PubMed]
26. Sang, J.; Acquaviva, J.; Friedland, J.C.; Smith, D.L.; Sequeira, M.; Zhang, C.; Jiang, Q.; Xue, L.; Lovly, C.M.; Jimenez, J.-P. et al. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov. 2013, 3, 430-443. [CrossRef] [PubMed]
27. Davies, H.; Bignell, G.R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M.J.; Bottomley, W. et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417, 949-954. [CrossRef] [PubMed]
28. Yuen, S.T.; Davies, H.; Chan, T.L.; Ho, J.W.; Bignell, G.R.; Cox, C.; Stephens, P.; Edkins, S.; Tsui, W.W.; Chan, A.S. et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res. 2002, 62, 6451-6455. [PubMed]
29. Kimura, E.T.; Nikiforova, M.N.; Zhu, Z.; Knauf, J.A.; Nikiforov, Y.E.; Fagin, J.A. High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003, 63, 1454-1457. [PubMed]
30. Hauschild, A.; Grob, J.-J.; Demidov, L.V.; Jouary, T.; Gutzmer, R.; Millward, M.; Rutkowski, P.; Blank, C.U.; Miller, W.H.; Kaempgen, E. et al. Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380, 358-365. [CrossRef] [PubMed]
31. McArthur, G.A.; Chapman, P.B.; Robert, C.; Larkin, J.; Haanen, J.B.; Dummer, R.; Ribas, A.; Hogg, D.; Hamid, O.; Ascierto, P.A. et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014, 15, 323-332. [CrossRef] [PubMed]
32. Naoki, K.; Chen, T.H.; Richards, W.G.; Sugarbaker, D.J.; Meyerson, M. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res. 2002, 62, 7001-7003. [PubMed]
33. Marchetti, A.; Felicioni, L.; Malatesta, S.; Grazia Sciarrotta, M.; Guetti, L.; Chella, A.; Viola, P.; Pullara, C.; Mucilli, F.; Buttitta, F. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J. Clin. Oncol. 2011, 29, 3574-3579. [CrossRef] [PubMed]
34. Paik, P.K.; Arcila, M.E.; Fara, M.; Sima, C.S.; Miller, V.A.; Kris, M.G.; Ladanyi, M.; Riely, G.J. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J. Clin. Oncol. 2011, 29, 2046-2051. [CrossRef] [PubMed]
35. Planchard, D.; Mazieres, J.; Riely, G.J.; Rudin, C.M.; Barlesi, F.; Quoix, E.A.; Souquet, P.J.; Socinski, M.A.; Switzky, J.; Ma, B. et al. Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) patients. J. Clin. Oncol. 2013, 31, 8009.
36. Robinson, S.D.; O’Shaughnessy, J.A.; Cowey, C.L.; Konduri, K. BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib. Lung Cancer 2014, 85, 326-330. [CrossRef] [PubMed]
37. Peters, S.; Michielin, O.; Zimmermann, S. Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. J. Clin. Oncol. 2013, 31, e341-e344. [CrossRef] [PubMed]
38. Bahadoran, P.; Allegra, M.; Le Duff, F.; Long-Mira, E.; Hofman, P.; Giacchero, D.; Passeron, T.; Lacour, J.-P.; Ballotti, R. Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma. J. Clin. Oncol. 2013, 31, e324-e326. [CrossRef] [PubMed]
39. Gautschi, O.; Pauli, C.; Strobel, K.; Hirschmann, A.; Printzen, G.; Aebi, S.; Diebold, J. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J. Thorac. Oncol. 2012, 7, e23-e24. [CrossRef] [PubMed]
40. Yang, H.; Higgins, B.; Kolinsky, K.; Packman, K.; Go, Z.; Iyer, R.; Kolis, S.; Zhao, S.; Lee, R.; Grippo, J.F. et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res. 2010, 70, 5518-5527. [CrossRef] [PubMed]
41. Gautschi, O.; Peters, S.; Zoete, V.; Aebersold-Keller, F.; Strobel, K.; Schwizer, B.; Hirschmann, A.; Michielin, O.; Diebold, J. Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib. Lung Cancer 2013, 82, 365-367. [CrossRef] [PubMed]
42. Schmid, S.; Siano, M.; Joerger, M.; Rodriguez, R.; Müller, J.; Früh, M. Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma. Lung Cancer 2015, 87, 85-87. [CrossRef] [PubMed]
43. Flaherty, K.T.; Robert, C.; Hersey, P.; Nathan, P.; Garbe, C.; Milhem, M.; Demidov, L.V.; Hassel, J.C.; Rutkowski, P.; Mohr, P. et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 2012, 367, 107-114. [CrossRef] [PubMed]
44. Pratilas, C.A.; Hanrahan, A.J.; Halilovic, E.; Persaud, Y.; Soh, J.; Chitale, D.; Shigematsu, H.; Yamamoto, H.; Sawai, A.; Janakiraman, M. et al. Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res. 2008, 68, 9375-9383. [CrossRef] [PubMed]
45. Joshi, M.; Rice, S.J.; Liu, X.; Miller, B.; Belani, C.P. Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer. PLoS ONE 2015, 10, e0118210. [CrossRef] [PubMed]
46. Santos, E.; Martin-Zanca, D.; Reddy, E.P.; Pierotti, M.A.; Della Porta, G.; Barbacid, M. Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science 1984, 223, 661-664. [CrossRef] [PubMed]
47. Sequist, L.V.; Heist, R.S.; Shaw, A.T.; Fidias, P.; Rosovsky, R.; Temel, J.S.; Lennes, I.T.; Digumarthy, S.; Waltman, B.A.; Bast, E. et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann. Oncol. 2011, 22, 2616-2624. [CrossRef] [PubMed]
48. Riely, G.J.; Kris, M.G.; Rosenbaum, D.; Marks, J.; Li, A.; Chitale, D.A.; Nafa, K.; Riedel, E.R.; Hsu, M.; Pao, W. et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin. Cancer Res. 2008, 14, 5731-5734. [CrossRef] [PubMed]
49. Sun, Y.; Ren, Y.; Fang, Z.; Li, C.; Fang, R.; Gao, B.; Han, X.; Tian, W.; Pao, W.; Chen, H. et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J. Clin. Oncol. 2010, 28, 4616-4620. [CrossRef] [PubMed]
50. Shepherd, F.A.; Domerg, C.; Hainaut, P.; Jänne, P.A.; Pignon, J.-P.; Graziano, S.; Douillard, J.-Y.; Brambilla, E.; Le Chevalier, T.; Seymour, L. et al. Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J. Clin. Oncol. 2013, 31, 2173-2181. [CrossRef] [PubMed]
51. Mascaux, C.; Iannino, N.; Martin, B.; Paesmans, M.; Berghmans, T.; Dusart, M.; Haller, A.; Lothaire, P.; Meert, A.-P.; Noel, S. et al. The role of RAS oncogene in survival of patients with lung cancer: A systematic review of the literature with meta-analysis. Br. J. Cancer 2005, 92, 131-139. [CrossRef] [PubMed]
52. Kalikaki, A.; Koutsopoulos, A.; Hatzidaki, D.; Trypaki, M.; Kontopodis, E.; Stathopoulos, E.; Mavroudis, D.; Georgoulias, V.; Voutsina, A. Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. Lung Cancer 2010, 69, 110-115. [CrossRef] [PubMed]
53. Camps, C.; Jantus-Lewintre, E.; Cabrera, A.; Blasco, A.; Sanmartín, E.; Gallach, S.; Caballero, C.; del Pozo, N.; Rosell, R.; Guijarro, R. et al. The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients. Lung Cancer 2011, 72, 365-369. [CrossRef] [PubMed]
54. Cappuzzo, F.; Ciuleanu, T.; Stelmakh, L.; Cicenas, S.; Szczesna, A.; Juhasz, E.; Esteban, E.; Molinier, O.; Brugger, W.; Melezinek, I. et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010, 11, 521-529. [CrossRef] [PubMed]
55. Pao, W.; Wang, T.Y.; Riely, G.J.; Miller, V.A.; Pan, Q.; Ladanyi, M.; Zakowski, M.F.; Heelan, R.T.; Kris, M.G.; Varmus, H.E. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005, 2, e17. [CrossRef] [PubMed]
56. Linardou, H.; Dahabreh, I.J.; Kanaloupiti, D.; Siannis, F.; Bafaloukos, D.; Kosmidis, P.; Papadimitriou, C.A.; Murray, S. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: A systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008, 9, 962-972. [CrossRef] [PubMed]
57. Adjei, A.A.; Mauer, A.; Bruzek, L.; Marks, R.S.; Hillman, S.; Geyer, S.; Hanson, L.J.; Wright, J.J.; Erlichman, C.; Kaufmann, S.H. et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 2003, 21, 1760-1766. [CrossRef] [PubMed]
58. Jänne, P.A.; Shaw, A.T.; Pereira, J.R.; Jeannin, G.; Vansteenkiste, J.; Barrios, C.; Franke, F.A.; Grinsted, L.; Zazulina, V.; Smith, P. et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: A randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 2013, 14, 38-47. [CrossRef] [PubMed]
59. Gandara, D.R.; Hiret, S.; Blumenschein, G.R.; Barlesi, F.; Delord, J.-P.; Madelaine, J.; Infante, J.R.; Reckamp, K.L.; Lara, P.; Audebert, C. et al. Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial. J. Clin. Oncol. 2013, 31, 8028.
60. Blumenschein, G.R.; Smit, E.F.; Planchard, D.; Kim, D.-W.; Cadranel, J.; de Pas, T.; Dunphy, F.; Udud, K.; Ahn, M.-J.; Hanna, N.H. et al. MEK114653, A randomized, multicenter, phase II study to assess efficacy and safety of trametinib (T) compared with docetaxel (D) in KRAS-mutant advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2013, 31, 8029.
61. Konstantinidou, G.; Bey, E.A.; Rabellino, A.; Schuster, K.; Maira, M.S.; Gazdar, A.F.; Amici, A.; Boothman, D.A.; Scaglioni, P.P. Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res. 2009, 69, 7644-7652. [CrossRef] [PubMed]
62. Konstantinidou, G.; Ramadori, G.; Torti, F.; Kangasniemi, K.; Ramirez, R.E.; Cai, Y.; Behrens, C.; Dellinger, M.T.; Brekken, R.A.; Wistuba, I.I. et al. RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas. Cancer Discov. 2013, 3, 444-457. [CrossRef] [PubMed]
63. Ostrem, J.M.; Peters, U.; Sos, M.L.; Wells, J.A.; Shokat, K.M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013, 503, 548-551. [CrossRef] [PubMed]
64. Hunter, J.C.; Gurbani, D.; Ficarro, S.B.; Carrasco, M.A.; Lim, S.M.; Choi, H.G.; Xie, T.; Marto, J.A.; Chen, Z.; Gray, N.S. et al. In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C. Proc. Natl. Acad. Sci. USA 2014, 111, 8895-8900. [CrossRef] [PubMed]
65. Ohashi, K.; Sequist L.V.; Arcila, M.E.; Lovly, C.M.; Chen, X.; Rudin, C.M.; Moran, T.; Camidge, D.R.; Vnencak-Jones, C.L.; Berry, L. et al. Characteristics of lung cancers harboring NRAS mutations. Clin. Cancer Res. 2013, 19, 2584-2591. [CrossRef] [PubMed]
66. Swain, S.M.; Kim, S.-B.; Cortés, J.; Ro, J.; Semiglazov, V.; Campone, M.; Ciruelos, E.; Ferrero, J.-.M.; Schneeweiss, A.; Knott, A. et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013, 14, 461-471. [CrossRef] [PubMed]
67. Verma, S.; Miles, D.; Gianni, L.; Krop, I.E.; Welslau, M.; Baselga, J.; Pegram, M.; Oh, D.-Y.; Diéras, V.; Guardino, E. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 2012, 367, 1783-1791. [CrossRef] [PubMed]
68. Geyer, C.E.; Forster, J.; Lindquist, D.; Chan, S.; Romieu, C.G.; Pienkowski, T.; Jagiello-Gruszfeld, A.; Crown, J.; Chan, A.; Kaufman, B. et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 2006, 355, 2733-2743. [CrossRef] [PubMed]
69. Hirsch, F.R.; Varella-Garcia, M.; Franklin, W.A.; Veve, R.; Chen, L.; Helfrich, B.; Zeng, C.; Baron, A.; Bunn, P.A.; Bunn, P.A., Jr. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br. J. Cancer 2002, 86, 1449-1456. [CrossRef] [PubMed]
70. Heinmoller, P.; Gross, C.; Beyser, K.; Schmidtgen, C.; Maass, G.; Pedrocchi, M.; Ruschoff, J. HER2 status in non-small cell lung cancer: Results from patient screening for enrollment to a phase II study of herceptin. Clin. Cancer Res. 2003, 9, 5238-5243. [PubMed]
71. Liu, L.; Shao, X.; Gao, W.; Bai, J.; Wang, R.; Huang, P.; Yin, Y.; Liu, P.; Shu, Y. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: A meta-analysis of published data. J. Thorac. Oncol. 2010, 5, 1922-1932. [CrossRef] [PubMed]
72. Arcila, M.E.; Chaft, J.E.; Nafa, K.L.; Roy-Chowdhuri, S.; Lau, C.; Zaidinski, M.; Paik, P.K.; Zakowski, M.F.; Kris, M.G.; Ladanyi, M. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin. Cancer Res. 2012, 18, 4910-4918. [CrossRef] [PubMed]
73. Stephens, P.; Hunter, C.; Bignell, G.; Edkins, S.; Davies, H.; Teague, J.; Stevens, C.; O’Meara, S.; Smith, R.; Parker, A. et al. Lung cancer: Intragenic ERBB2 kinase mutations in tumours. Nature 2004, 431, 525-526. [CrossRef] [PubMed]
74. Shigematsu, H.; Takahashi, T.; Nomura, M.; Majmudar, K.; Suzuki, M.; Lee, H.; Wistuba, I.I.; Fong, K.M.; Toyooka, S.; Shimizu, N. et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 2005, 65, 1642-1646. [CrossRef] [PubMed]
75. Gatzemeier, U.; Groth, G.; Butts, C.; van Zandwijk, N.; Shepherd, F.; Ardizzoni, A.; Barton, C.; Ghahramani, P.; Hirsh, V. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann. Oncol. 2004, 15, 19-27. [CrossRef] [PubMed]
76. Zinner, R.G.; Glisson, B.S.; Fossella, F.V.; Pisters, K.M.W.; Kies, M.S.; Lee, P.M.; Massarelli, E.; Sabloff, B.; Fritsche, H.A.; Ro, J.Y. et al. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: Report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing d. Lung Cancer 2004, 44, 99-110. [CrossRef] [PubMed]
77. Ross, H.J.; Blumenschein, G.R.; Aisner, J.; Damjanov, N.; Dowlati, A.; Garst, J.; Rigas, J.R.; Smylie, M.; Hassani, H.; Allen, K.E. et al. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clin. Cancer Res. 2010, 16, 1938-1949. [CrossRef] [PubMed]
78. Mazières, J.; Peters, S.; Lepage, B.; Cortot, A.B.; Barlesi, F.; Beau-Faller, M.; Besse, B.; Blons, H.; Mansuet-Lupo, A.; Urban, T. et al. Lung cancer that harbors an HER2 mutation: Epidemiologic characteristics and therapeutic perspectives. J. Clin. Oncol. 2013, 31, 1997-2003. [CrossRef] [PubMed]
79. De Grève, J.; Teugels, E.; Geers, C.; Decoster, L.; Galdermans, D.; de Mey, J.; Everaert, H.; Umelo, I.; In’t Veld, P.; Schallier, D. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer 2012, 76, 123-127. [CrossRef] [PubMed]
80. Gandhi, L.; Bahleda, R.; Tolaney, S.M.; Kwak, E.L.; Cleary, J.M.; Pandya, S.S.; Hollebecque, A.; Abbas, R.; Ananthakrishnan, R.; Berkenblit, A. et al. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J. Clin. Oncol. 2013, 32, 68-75. [CrossRef] [PubMed]
81. Onozato, R.; Kosaka, T.; Kuwano, H.; Sekido, Y.; Yatabe, Y.; Mitsudomi, T. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J. Thorac. Oncol. 2009, 4, 5-11. [CrossRef] [PubMed]
82. Seo, J.-S.; Ju, Y.S.; Lee, W.-C.; Shin, J.-Y.; Lee, J.K.; Bleazard, T.; Lee, J.; Jung, Y.J.; Kim, J.-O.; Shin, J.-Y. et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res. 2012, 22, 2109-2119. [CrossRef] [PubMed]
83. Beau-Faller, M.; Ruppert, A.-M.; Voegeli, A.-C.; Neuville, A.; Meyer, N.; Guerin, E.; Legrain, M.; Mennecier, B.; Wihlm, J.-M.; Massard, G. et al. MET gene copy number in non-small cell lung cancer: Molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort. J. Thorac. Oncol. 2008, 3, 331-339. [CrossRef] [PubMed]
84. Cappuzzo, F.; Marchetti, A.; Skokan, M.; Rossi, E.; Gajapathy, S.; Felicioni, L.; Del Grammastro, M.; Sciarrotta, M.G.; Buttitta, F.; Incarbone, M. et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J. Clin. Oncol. 2009, 27, 1667-1674. [CrossRef] [PubMed]
85. Tsao, M.S.; Liu, N.; Chen, J.R.; Pappas, J.; Ho, J.; To, C.; Viallet, J.; Park, M.; Zhu, H. Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers. Lung Cancer 1998, 20, 1-16. [CrossRef] [PubMed]
86. Ichimura, E.; Maeshima, A.; Nakajima, T.; Nakamura, T. Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn. J. Cancer Res. 1996, 87, 1063-1069. [CrossRef] [PubMed]
87. Engelman, J.A.; Zejnullahu, K.; Mitsudomi, T.; Song, Y.; Hyland, C.; Park, J.O.; Lindeman, N.; Gale, C.-M.M.; Zhao, X.; Christensen, J. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316, 1039-1043. [CrossRef] [PubMed]
88. Bean, J.; Brennan, C.; Shih, J.-Y.; Riely, G.; Viale, A.; Wang, L.; Chitale, D.; Motoi, N.; Szoke, J.; Broderick, S. et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. USA 2007, 104, 20932-20937. [CrossRef] [PubMed]
89. Spigel, D.R.; Ervin, T.J.; Ramlau, R.A.; Daniel, D.B.; Goldschmidt, J.H., Jr.; Blumenschein, G.R., Jr.; Krzakowski, M.J.; Robinet, G.; Godbert, B.; Barlesi, F. et al. Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 2013. [CrossRef]
90. Spigel, D.R.; Edelman, M.J.; O’Byrne, K.; Paz-Ares, L.; Shames, D.S.; Yu, W.; Paton, V.E.; Mok, T.; Sarah Cannon Research Institute; Nashville, T.N. et al. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial. J. Clin. Oncol. 2014, 32, 8000. [CrossRef]
91. Patnaik, A.; Weiss, G.J.; Papadopoulos, K.P.; Hofmeister, C.C.; Tibes, R.; Tolcher, A.; Isaacs, R.; Jac, J.; Han, M.; Payumo, F.C. et al. Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma. Br. J. Cancer 2014, 111, 272-280. [CrossRef] [PubMed]
92. Gordon, M.S.; Sweeney, C.S.; Mendelson, D.S.; Eckhardt, S.G.; Anderson, A.; Beaupre, D.M.; Branstetter, D.; Burgess, T.L.; Coxon, A.; Deng, H. et al. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin. Cancer Res. 2010, 16, 699-710. [CrossRef] [PubMed]
93. Sequist, L.V.; von Pawel, J.; Garmey, E.G.; Akerley, W.L.; Brugger, W.; Ferrari, D.; Chen, Y.; Costa, D.B.; Gerber, D.E.; Orlov, S. et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J. Clin. Oncol. 2011, 29, 3307-3315. [CrossRef] [PubMed]
94. Scagliotti, G.; Novello, S.; Ramlau, R.; Favaretto, A.; Barlesi, F.; Akerley, W.; von Pawel, J.; Shuster, D.; Schwartz, B.; Sandler, A. MARQUEE: A randomized, double-blind, placebo-controlled, phase 3 trial of tivantinib (ARQ 197) plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, non-squamous, non-small-cell lung cancer (NSCLC). In Proceedings of the 17th ECCO-38th ESMO-32nd ESTRO European Cancer Congress 2013, Amsterdam, The Netherlands, 27 September-1 October 2013.
95. Calles, A.; Kwiatkowski, N.; Cammarata, B.K.; Ercan, D.; Gray, N.S.; Jänne, P.A. Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines. Mol. Oncol. 2015, 9, 260-269. [CrossRef] [PubMed]
96. Zou, H.Y.; Li, Q.; Lee, J.H.; Arango, M.E.; McDonnell, S.R.; Yamazaki, S.; Koudriakova, T.B.; Alton, G.; Cui, J.J.; Kung, P.P. et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007, 67, 4408-4417. [CrossRef] [PubMed]
97. Ou, S.H.; Kwak, E.L.; Siwak-Tapp, C.; Dy, J.; Bergethon, K.; Clark, J.W.; Camidge, D.R.; Solomon, B.J.; Maki, R.G.; Bang, Y.J. et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J. Thorac. Oncol. 2011, 6, 942-946. [CrossRef] [PubMed]
98. Wells, S.A., Jr.; Santoro, M. Targeting the RET pathway in thyroid cancer. Clin. Cancer Res. 2009, 15, 7119-7123. [CrossRef] [PubMed]
99. Santoro, M.; Chiappetta, G.; Cerrato, A.; Salvatore, D.; Zhang, L.; Manzo, G.; Picone, A.; Portella, G.; Santelli, G.; Vecchio, G. et al. Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Oncogene 1996, 12, 1821-1826. [PubMed]
100. Wang, R.; Hu, H.; Pan, Y.; Li, Y.; Ye, T.; Li, C.; Luo, X.; Wang, L.; Li, H.; Zhang, Y. et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J. Clin. Oncol. 2012, 30, 4352-4359. [CrossRef] [PubMed]
101. Varella-Garcia, M.; Xu, L.G.; Mahale, S.; Berge, E.M.; Bennati, C.; Le, A.T.; Aisner, D.; Crinò, L.; Bunn, P.A.; Camidge, D.R. et al. RET rearrangements detected by FISH in “pan-negative” lung adenocarcinoma. J. Clin. Oncol. 2013, 31, 8024.
102. Lipson, D.; Capelletti, M.; Yelensky, R.; Otto, G.; Parker, A.; Jarosz, M.; Curran, J.A.; Balasubramanian, S.; Bloom, T.; Brennan, K.W. et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat. Med. 2012, 18, 382-384. [CrossRef] [PubMed]
103. Kohno, T.; Ichikawa, H.; Totoki, Y.; Yasuda, K.; Hiramoto, M.; Nammo, T.; Sakamoto, H.; Tsuta, K.; Furuta, K.; Shimada, Y. et al. KIF5B-RET fusions in lung adenocarcinoma. Nat. Med. 2012, 18, 375-377. [CrossRef] [PubMed]
104. Drilon, A.; Wang, L.; Hasanovic, A.; Suehara, Y.; Lipson, D.; Stephens, P.; Ross, J.; Miller, V.; Ginsberg, M.; Zakowski, M.F. et al. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov. 2013, 3, 630-635. [CrossRef] [PubMed]
105. Suzuki, M.; Makinoshima, H.; Matsumoto, S.; Suzuki, A.; Mimaki, S.; Matsushima, K.; Yoh, K.; Goto, K.; Suzuki, Y.; Ishii, G. et al. Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo. Cancer Sci. 2013, 104, 896-903. [CrossRef] [PubMed]
106. Kodama, T.; Tsukaguchi, T.; Satoh, Y.; Yoshida, M.; Watanabe, Y.; Kondoh, O.; Sakamoto, H. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer. Mol. Cancer Ther. 2014, 13, 2910-2918. [CrossRef] [PubMed]
107. Falchook, G.S.; Ordóñez, N.G.; Bastida, C.C.; Stephens, P.J.; Miller, V.A.; Gaido, L.; Jackson, T.; Karp, D.D. Effect of the RET inhibitor vandetanib in a patient with RET fusion-positive metastatic non-small-cell lung cancer. J. Clin. Oncol. 2014. [CrossRef]
108. Gautschi, O.; Zander, T.; Keller, F.A.; Strobel, K.; Hirschmann, A.; Aebi, S.; Diebold, J. A patient with lung adenocarcinoma and RET fusion treated with vandetanib. J. Thorac. Oncol. 2013, 8, e43-e44. [CrossRef] [PubMed]
109. Kawano, O.; Sasaki, H.; Endo, K.; Suzuki, E.; Haneda, H.; Yukiue, H.; Kobayashi, Y.; Yano, M.; Fujii, Y. PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer 2006, 54, 209-215. [CrossRef] [PubMed]
110. Kawano, O.; Sasaki, H.; Okuda, K.; Yukiue, H.; Yokoyama, T.; Yano, M.; Fujii, Y. PIK3CA gene amplification in Japanese non-small cell lung cancer. Lung Cancer 2007, 58, 159-160. [CrossRef] [PubMed]
111. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, 489, 519-525. [CrossRef] [PubMed]
112. Chaft, J.E.; Arcila, M.E.; Paik, P.K.; Lau, C.; Riely, G.J.; Pietanza, M.C.; Zakowski, M.F.; Rusch, V.; Sima, C.S.; Ladanyi, M. et al. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Mol. Cancer Ther. 2012, 11, 485-491. [CrossRef] [PubMed]
113. Sequist, L.V.; Waltman, B.A.; Dias-Santagata, D.; Digumarthy, S.; Turke, A.B.; Fidias, P.; Bergethon, K.; Shaw, A.T.; Gettinger, S.; Cosper, A.K. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 2011, 3, 75ra26. [CrossRef] [PubMed]
114. Engelman, J.A.; Chen, L.; Tan, X.; Crosby, K.; Guimaraes, A.R.; Upadhyay, R.; Maira, M.; McNamara, K.; Perera, S.A.; Song, Y. et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 2008, 14, 1351-1356. [CrossRef] [PubMed]
115. Dutt, A.; Ramos, A.H.; Hammerman, P.S.; Mermel, C.; Cho, J.; Sharifnia, T.; Chande, A.; Tanaka, K.E.; Stransky, N.; Greulich, H. et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS ONE 2011, 6, e20351. [CrossRef] [PubMed]
116. Weiss, J.; Sos, M.L.; Seidel, D.; Peifer, M.; Zander, T.; Heuckmann, J.M.; Ullrich, R.T.; Menon, R.; Maier, S.; Soltermann, A. et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci. Transl. Med. 2010, 2, 62ra93. [CrossRef] [PubMed]
117. Kim, H.R.; Kim, D.J.; Kang, D.R.; Lee, J.G.; Lim, S.M.; Lee, C.Y.; Rha, S.Y.; Bae, M.K.; Lee, Y.J.; Kim, S.H. et al. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J. Clin. Oncol. 2013, 31, 731-737. [CrossRef] [PubMed]
118. Heist, R.S.; Mino-Kenudson, M.; Sequist, L.V.; Tammireddy, S.; Morrissey, L.; Christiani, D.C.; Engelman, J.A.; Iafrate, A.J. FGFR1 amplification in squamous cell carcinoma of the lung. J. Thorac. Oncol. 2012, 7, 1775-1780. [CrossRef] [PubMed]
119. Liao, R.G.; Jung, J.; Tchaicha, J.; Wilkerson, M.D.; Sivachenko, A.; Beauchamp, E.M.; Liu, Q.; Pugh, T.J.; Pedamallu, C.S.; Hayes, D.N. et al. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res. 2013, 73, 5195-5205. [CrossRef] [PubMed]
120. Vogel, W. Discoidin domain receptors: structural relations and functional implications. FASEB J. 1999, 13, S77-S82. [PubMed]
121. Hammerman, P.S.; Sos, M.L.; Ramos, A.H.; Xu, C.; Dutt, A.; Zhou, W.; Brace, L.E.; Woods, B.A.; Lin, W.; Zhang, J. et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 2011, 1, 78-89. [CrossRef] [PubMed]
122. Marks, J.L.; Gong, Y.; Chitale, D.; Golas, B.; McLellan, M.D.; Kasai, Y.; Ding, L.; Mardis, E.R.; Wilson, R.K.; Solit, D. et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008, 68, 5524-5528. [CrossRef] [PubMed]
123. Vaishnavi, A.; Capelletti, M.; Le, A.T.; Kako, S.; Butaney, M.; Ercan, D.; Mahale, S.; Davies, K.D.; Aisner, D.L.; Pilling, A.B. et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat. Med. 2013, 19, 1469-1472. [CrossRef] [PubMed]
124. De Braud, F.G.; Pilla, L.; Niger, M.; Damian, S.; Bardazza, B.; Martinetti, A.; Pelosi, G.; Marrapese, G.; Palmeri, L.; Cerea, G. et al. Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. J. Clin. Oncol. 2014, 32, 2502.
125. Tang, J.-M.; He, Q.-Y.; Guo, R.-X.; Chang, X.-J. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 2006, 51, 181-191. [CrossRef] [PubMed]
126. Jin, G.; Kim, M.J.; Jeon, H.-S.; Choi, J.E.; Kim, D.S.; Lee, E.B.; Cha, S.I.; Yoon, G.S.; Kim, C.H.; Jung, T.H. et al. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer 2010, 69, 279-283. [CrossRef] [PubMed]
127. Ding, L.; Getz, G.; Wheeler, D.A.; Mardis, E.R.; McLellan, M.D.; Cibulskis, K.; Sougnez, C.; Greulich, H.; Muzny, D.M.; Morgan, M.B. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455, 1069-1075. [CrossRef] [PubMed]
128. Kim, S.C.; Jung, Y.; Park, J.; Cho, S.; Seo, C.; Kim, J.; Kim, P.; Park, J.; Seo, J.; Kim, J. et al. A high-dimensional, deep-sequencing study of lung adenocarcinoma in female never-smokers. PLoS ONE 2013, 8, e55596. [CrossRef] [PubMed]
129. The Clinical Lung Cancer Genome Project (CLCGP) and Network Genomic Medicine (NGM). A genomics-based classification of human lung tumors. Sci. Transl. Med. 2013, 5, 209ra153. [PubMed]
130. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer; NCCN: Fort Washington, PA, USA, 2015.
131. Redig, A.J.; Jänne, P.A. Basket trials and the evolution of clinical trial design in an era of genomic medicine. J. Clin. Oncol. 2015. [CrossRef]
132. Lopez-Chavez, A.; Thomas, A.; Rajan, A.; Raffeld, M.; Morrow, B.; Kelly, R.; Carter, C.A.; Guha, U.; Killian, K.; Lau, C.C. et al. Molecular profiling and targeted therapy for advanced thoracic malignancies: A Biomarker-derived, multiarm, multihistology phase II basket trial. J. Clin. Oncol. 2015, 33, 1000-1007. [CrossRef] [PubMed]